Roquefort/Lyramid postings, page-147

Whenever I think about this useless thread, I then think about Halasz, Walton and Wuurman going to "Big Pharma" with Lyramid for sale or rent.

Cancer treatments themselves are worth billions as Roquefort tells us, so why the lack of interest from the big end of town three years ago? If they did not already know about the adverse properties of Midkine then that huge news would have been worth looking into. So did they look into it. Or did they already know about it and have it under control?

In the early days, it was found that some cancer cells,as well as having some additional adverse properties, also have some of the same properties that exist in normal cells, but because of the rapid division and multiplication of cancer cells, those normal properties could be used for drug treatment. Cells ensuring that, upon division, new cell walls are correctly formed, new blood supplies are correctly built, DNA from RNA is correctly strung together, could be killed without too much harm to the host whose normal cells were dividing at a much slower rate. And many drugs were marketed to do just that. And that is apart from the next generation drugs now treating with next generation further nucleic and biochemical discoveries. There was not, and is not, the presence of drugs that SPECIFICALLY target that extra adverse property of some cells, that is...... the production of Midkine.

So, why the lack of interest from "big Pharma"? Cellmid/AN1 could have been bought with their petty cash if it was important enough.

They already knew about it, and had it under control. IMO

Midkine is a fine biomarker for disease as we know from PEB. "Big Pharma" would have already trialled extensively for Midkine presence in cancer patients and other patients.

'What is the presence of Midkine in those patients receiving the new or existing drug, and what is the presence of Midkine in those patients in the same trial not receiving the new or existing drug". This would have been the ongoing question.

Roquefort has announced that it has trialled a drug or drugs that, in vitro, can modify the Midkine molecule produced by a cancer cell. Well, It has all been done before, only better.

Midkine is NOT present in patients receiving some drugs that are already in clinical use when it would be expected to be present. So why is it not present? Well, because cells that happen to produce Midkine are luckily being dealt with because they are being targeted for some OTHER adverse property that they display. Therefore Lyramid was knocked back when offered to "Big Pharma". "Big Pharma" obviously did not need Lyramid three years ago. And, IMO,still doesn't.

Because, Midkine producing cells are already collaterally being dealt with by drugs that are already in clinical use for something else!! IMO

Is it likely that Roquefort's knowledge is ahead of that of PEB and "Big Pharma"?

Just think about the knowledge that PEB must have about Midkine. The message would have been passed on to its sponsor and others years ago if Lyramid/Midkine had any value at all in disease TREATMENT.